What Are the Benefits of Gene Therapy? 9 Advantages Changing Medicine

Billy Odell Tucker-Robinson Founder & Host — Banking With Billy Network • Intelligence Network • Data Science • AI Research • World News
Published: 2026-09-25T22:45:39.125Z • Permanent link

In 2018, CRISPR Therapeutics and Editas Medicine, two pioneering biotech companies, announced a landmark collaboration to develop a gene therapy for sickle cell disease. This bold move marked a significant milestone in the rapidly evolving field of gene editing, which has since captured the attention of researchers, investors, and patients worldwide. Led by visionaries like Dr. David Liu, a renowned chemist and gene editor, the CRISPR-Cas13 system has become a go-to tool for precision genome editing. By harnessing the power of CRISPR, scientists can now target specific genes with unprecedented accuracy, opening doors to novel treatments for a wide range of diseases.

Meanwhile, in the United States, the FDA has been actively promoting the development of gene therapies, issuing guidance and regulations to facilitate the rapid advancement of the field. In 2020, the FDA approved the first-ever gene therapy for a genetic disorder, Luxturna, developed by Novartis. This approval marked a significant turning point, paving the way for more gene therapies to enter the market. The approval of Luxturna was also a testament to the collaborative efforts of researchers, regulators, and industry leaders, who worked together to bring this groundbreaking treatment to patients in need.

In the UK, the National Health Service (NHS) has also taken a keen interest in gene therapy, with several trials currently underway to test the efficacy of gene editing technologies in treating rare genetic disorders. The NHS's willingness to invest in gene therapy research reflects the growing recognition of the potential benefits of these technologies in improving patient outcomes. As the field continues to evolve, it is likely that we will see more institutions and governments embracing gene therapy as a vital tool in the fight against disease.

The advent of gene therapy has far-reaching implications for the biotech and medical industries. Companies like BioNTech and Pfizer are already leveraging gene editing technologies to develop innovative treatments for a range of diseases, from cancer to rare genetic disorders. The approval of Luxturna has also sparked a flurry of interest in gene therapy, with several other treatments currently in various stages of development. As the field continues to mature, we can expect to see significant investments in gene therapy research, driving innovation and improving patient outcomes.

The impact of gene therapy on the pharmaceutical industry will also be significant, with many established companies looking to adapt their business models to take advantage of the emerging landscape. For instance, Pfizer has already launched a dedicated gene therapy platform, which will enable the company to develop and commercialize gene editing technologies. As the biotech industry continues to evolve, it is likely that we will see more companies entering the space, driving competition and innovation.

Gene therapy's emergence as a major force in biotech and medicine is not a new phenomenon. In the 1980s, the first gene therapy trials were conducted, but the technology was hampered by technical limitations and regulatory hurdles. However, with the advent of CRISPR-Cas9 in 2012, the field has experienced a renaissance, with scientists and clinicians rapidly developing new applications for gene editing. Today, gene therapy is recognized as a critical component of modern medicine, with the potential to transform the treatment of genetic disorders.